There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure
with mild to moderate hepatic encephalopathy will be enrolled in this study according to the
inclusion and exclusion criteria, and will be randomly divided into two groups as 1:1.First
group is called Rifaximin group, on the basis of comprehensive treatment of liver failure,
Rifaximin (Alfa Sigma S.p.A) is added, three times a day, 400 mg each time, for a total of 4
weeks, and observed until 12 weeks after withdrawal. The other group is called standard
treatment group (control group), which will receive routine comprehensive treatment for liver
failure. The reversal of mild to moderate hepatic encephalopathy in the two groups of
patients will be observed within 4 weeks, then follow up to 12 weeks.